These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 7630741)
1. Somatostatin receptor expression in the thyroid demonstrated with 111In-octreotide scintigraphy. Becker W; Schrell U; Buchfelder M; Hensen J; Wendler J; Gramatzki M; Wolf F Nuklearmedizin; 1995 Jun; 34(3):100-3. PubMed ID: 7630741 [TBL] [Abstract][Full Text] [Related]
2. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? Postema PT; Krenning EP; Wijngaarde R; Kooy PP; Oei HY; van den Bosch WA; Reubi JC; Wiersinga WM; Hooijkaas H; van der Loos T J Clin Endocrinol Metab; 1994 Dec; 79(6):1845-51. PubMed ID: 7989493 [TBL] [Abstract][Full Text] [Related]
3. Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies. Lincke T; Singer J; Kluge R; Sabri O; Paschke R Thyroid; 2009 Apr; 19(4):381-9. PubMed ID: 19355828 [TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide. Breeman WA; van Hagen PM; Kwekkeboom DJ; Visser TJ; Krenning EP Eur J Nucl Med; 1998 Feb; 25(2):182-6. PubMed ID: 9473268 [TBL] [Abstract][Full Text] [Related]
5. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy]. Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648 [TBL] [Abstract][Full Text] [Related]
6. [Accumulation of radioactivity in the lung after 111In-octreotide scintigraphy]. Schleicher UM; Cremerius U; Schubert H Rofo; 1998 Apr; 168(4):404-6. PubMed ID: 9589108 [No Abstract] [Full Text] [Related]
7. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343 [TBL] [Abstract][Full Text] [Related]
8. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310 [TBL] [Abstract][Full Text] [Related]
9. 111In-octreotide in the evaluation of autoimmune thyroid diseases. Mansi L; Rambaldi PF; Bizzarro A; Panza N; Del Vecchio E Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):127-30. PubMed ID: 9002770 [TBL] [Abstract][Full Text] [Related]
10. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. Tenenbaum F; Lumbroso J; Schlumberger M; Caillou B; Fragu P; Parmentier C J Nucl Med; 1995 May; 36(5):807-10. PubMed ID: 7738653 [TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Krassas GE; Dumas A; Pontikides N; Kaltsas T Clin Endocrinol (Oxf); 1995 Jun; 42(6):571-80. PubMed ID: 7634496 [TBL] [Abstract][Full Text] [Related]
12. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors. Ronga G; Salerno G; Procaccini E; Mauro L; Annovazzi A; Barone R; Mellozzi M; Tamburrano G; Signore A Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):134-6. PubMed ID: 9002772 [TBL] [Abstract][Full Text] [Related]
13. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC). Kurtaran A; Leimer M; Kaserer K; Yang Q; Angelberger P; Niederle B; Virgolini I Nucl Med Biol; 1996 May; 23(4):503-7. PubMed ID: 8832707 [TBL] [Abstract][Full Text] [Related]